Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Chapter 1: The management of erectile dysfunction: an AUA update.

Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID; Erectile Dysfunction Guideline Update Panel..

J Urol. 2005 Jul;174(1):230-9. No abstract available.

PMID:
15947645
2.
3.

The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.

Montorsi F, Briganti A, Salonia A, Montorsi P, Rigatti P.

Curr Opin Urol. 2004 Nov;14(6):357-9. Review. No abstract available.

PMID:
15626879
4.

An update on the PDE-5 inhibitors (PDE-5i).

McCullough AR.

J Androl. 2003 Nov-Dec;24(6 Suppl):S52-8. Review. No abstract available.

5.

[The treatment options broaden. New chances for libido].

Einecke U.

MMW Fortschr Med. 2002 May 9;144(19):4-6. German. No abstract available.

PMID:
12116552
6.

Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction.

Corbin JD, Francis SH.

J Androl. 2003 Nov-Dec;24(6 Suppl):S38-41. Review. No abstract available.

7.

[Erectile dysfunction and phosphodiesterase type 5 inhibitors].

Roumeguère T, Sternon J, Schulman CC.

Rev Med Brux. 2003 Jun;24(3):169-75. Review. French.

PMID:
12891884
8.

PDE-5 inhibitors: current status and future trends.

Masson P, Lambert SM, Brown M, Shabsigh R.

Urol Clin North Am. 2005 Nov;32(4):511-25, viii. Review.

PMID:
16291042
9.

[How I treat and manage erectile dysfunction in diabetics].

Buvat J.

Journ Annu Diabetol Hotel Dieu. 2006:185-203. Review. French. No abstract available.

PMID:
17051861
10.

Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.

Sommer F, Schulze W.

World J Urol. 2005 Dec;23(6):385-92. Epub 2005 Nov 5. Review.

PMID:
16273418
11.

[Diagnosis of erectile dysfunction--what is still needed today?].

Weiske WH.

Urologe A. 2003 Oct;42(10):1317-21. German.

PMID:
14569379
12.

Phosphodiesterase type 5 (PDE5) inhibitors.

Haning H, Niewöhner U, Bischoff E.

Prog Med Chem. 2003;41:249-306. Review. No abstract available.

PMID:
12774696
13.

[Some aspects of erectile dysfunction pathogenesis and treatment in patients with obesity].

Ametov AS, Teodorovich OV, Kondrat'eva LV, Popova AIu.

Ter Arkh. 2006;78(2):92-4. Review. Russian. No abstract available.

PMID:
16613108
14.

Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.

Lobo JR, Nehra A.

Urol Clin North Am. 2005 Nov;32(4):447-55, vi. Review.

PMID:
16291036
15.

Erectile dysfunction.

Shabsigh R, Anastasiadis AG.

Annu Rev Med. 2003;54:153-68. Epub 2002 Aug 19. Review.

PMID:
12525671
16.

Phosphodiesterase inhibitors for the treatment of erectile dysfunction.

Küthe A, Montorsi F, Andersson KE, Stief CG.

Curr Opin Investig Drugs. 2002 Oct;3(10):1489-95. Review.

PMID:
12431025
17.

PDE5 inhibitors: looking beyond ED.

Jackson G.

Int J Clin Pract. 2003 Apr;57(3):159-60. No abstract available.

PMID:
12723713
18.

Nitric oxide regulation of penile erection: biology and therapeutic implications.

Burnett AL.

J Androl. 2002 Sep-Oct;23(5):S20-6. Review. No abstract available.

19.

[Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].

[No authors listed]

MMW Fortschr Med. 2004 Apr 15;146(16):62. German. No abstract available.

PMID:
15222506
20.

Phosphodiesterase type 5 inhibitors for erectile dysfunction.

Carson CC, Lue TF.

BJU Int. 2005 Aug;96(3):257-80. Review.

Supplemental Content

Support Center